Change of Macular Pigment Optical Density After Intravitreal Triamcinolon Injection Treatment

Change of Macular Pigment Optical Density After Intravitreal Triamcinolon Injection Treatment in Patient with Diabetic Macular Edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004230

Enrollment

Registered

2019-08-21

Start date

2022-02-28

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patient with diabetic macular edmea who needs treatment Triamcinolone acetonide(MaQaid®, Wakamoto Pharmaceutical Co., Ltd., Tokyo, Japan)/dosage 0.1 mL/Single injection/Intravitreal injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. A person who meets the following criteria (1) a person diagnosed with diabetic and macular edema (2) inovolved at least one eye (3) central macular thickness is 300 or more by optical coherence tomography 2. Adult, the age of twenty or more 3. Patients with visual acuity less than or equal to 20/40 (Snellen) in the pathologic eye 4. Patients who voluntarily decided to participate in the study and signed a consent form

Exclusion criteria

Exclusion criteria: 1. Pregnant state 2. Previous vitrectomy history 3. Previous history of intravitreal triamcinolone injection due to diabetic macular edema 4. Macular edema caused by other than diabetes 5. Diagnosed or treatment for other ocular cormorbidity such as, Intermediate or advanced dry age related macular degeneration (ARMD), exudative ARMD, vitreous hemorrhage, retinal vein occlusion, uveitis, retinal dystrophy, ocular trauma, optic nerve atrophy, intraocular tumor, corneal opacity 6. Ongoing diagnosed or suspcious intraocular or periocular infection 7. Uncontrolled glaucoma, Intraocular pressure over 21mmHg even with appropriate use of intraocular pressure lowering agents. History of glaucoma surgery due to steroid induced glaucoma 8. Chronic alcoholics or psychiatric state that could affact the study process. 9. Patients who thought to be not able to complete study process or have a medical condition is unsuitable for study process by clinicion's opinion 10. Uptaking lutein or other medication which affect macular pigment optical density.

Design outcomes

Primary

Measure	Time frame
macular pigment optical density(MPOD) after 4, 12 weeks from intravitreal injection	—

Secondary

Measure	Time frame
Central macular thickness;best corrected visual acuity	—

Countries

Korea, Republic of

Contacts

Public ContactRae-Young Kim

The Catholic University of Korea, Seoul St. Mary's Hospital

raeyoungk07@gmail.com+82-2-2258-6349

Outcome results